
According to data from Benzinga Pro, during Q1, ANI Pharmaceuticals's (NASDAQ:ANIP) reported sales totaled $64.48 million. Despite a 16.6% increase in earnings, the company posted a loss of $20.13 million. ANI Pharmaceuticals collected $60.93 million in revenue during Q4, but reported earnings showed a $24.14 million loss.